US Supreme Court to hear Teva’s appeal on Copaxone patent
The 808 patent expires on 01 September 2015 and claims a process for manufacturing the active ingredient of the company’s relapsing-remitting multiple sclerosis (RRMS) product, Copaxone (glatiramer acetate
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.